MX365097B - Formulacion de implantes de paliperidona. - Google Patents
Formulacion de implantes de paliperidona.Info
- Publication number
- MX365097B MX365097B MX2014014484A MX2014014484A MX365097B MX 365097 B MX365097 B MX 365097B MX 2014014484 A MX2014014484 A MX 2014014484A MX 2014014484 A MX2014014484 A MX 2014014484A MX 365097 B MX365097 B MX 365097B
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- lactic
- weeks
- drug
- glycolic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Una composición de liberación sostenida inyectable por vía intramuscular adecuada para la formación de un implante sólido in situ en un organismo, que comprende un fármaco que es paliperidona y/o sus sales farmacéuticamente aceptables en cualquier combinación de las mismas, un copolímero biocompatible a base de ácido láctico y ácido glicólico con una relación monomérica entre el ácido láctico y el ácido glicólico en el intervalo de 50:50 y DMSO como disolvente, que se caracteriza porque la composición libera el fármaco con un comienzo inmediato de la acción y de manera continua durante al menos ocho semanas y que se caracteriza porque la composición tiene un perfil farmacocinético in vivo adecuado para la administración de la formulación cada ocho semanas o periodos aún más largos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170366.4A EP2529757B1 (en) | 2011-05-31 | 2012-05-31 | Paliperidone implant formulation |
| PCT/EP2013/061319 WO2013178811A1 (en) | 2012-05-31 | 2013-05-31 | Paliperidone implant formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014014484A MX2014014484A (es) | 2015-02-24 |
| MX365097B true MX365097B (es) | 2019-05-22 |
Family
ID=47074463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014484A MX365097B (es) | 2012-05-31 | 2013-05-31 | Formulacion de implantes de paliperidona. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP2529757B1 (es) |
| JP (1) | JP6430933B2 (es) |
| KR (1) | KR101892496B1 (es) |
| CN (2) | CN109966239A (es) |
| AU (1) | AU2013269546B2 (es) |
| BR (1) | BR112014029208B1 (es) |
| CA (1) | CA2874702C (es) |
| CL (1) | CL2014003215A1 (es) |
| CO (1) | CO7160109A2 (es) |
| CY (1) | CY1114975T1 (es) |
| DK (1) | DK2529757T3 (es) |
| EA (1) | EA029921B1 (es) |
| ES (1) | ES2456917T3 (es) |
| HR (1) | HRP20140158T1 (es) |
| IL (1) | IL235850A0 (es) |
| IN (1) | IN2014DN10673A (es) |
| MA (1) | MA37661B1 (es) |
| MX (1) | MX365097B (es) |
| MY (1) | MY181549A (es) |
| NZ (1) | NZ703319A (es) |
| PH (1) | PH12014502668A1 (es) |
| PL (1) | PL2529757T3 (es) |
| PT (1) | PT2529757E (es) |
| SG (1) | SG11201407971QA (es) |
| SI (1) | SI2529757T1 (es) |
| SM (1) | SMT201400044B (es) |
| UA (1) | UA115987C2 (es) |
| WO (1) | WO2013178811A1 (es) |
| ZA (1) | ZA201409297B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| LT2394663T (lt) | 2010-05-31 | 2022-02-10 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| SI2529756T1 (sl) * | 2011-05-31 | 2021-09-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija vsadka z risperidonom in/ali paliperidonom |
| ES2456917T3 (es) * | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
| ES2802299T3 (es) * | 2015-04-07 | 2021-01-18 | Janssen Pharmaceuticals Inc | Régimen de dosificación para dosis olvidadas para ésteres de paliperidona inyectables de acción prolongada |
| CN106038569A (zh) * | 2016-05-26 | 2016-10-26 | 湖南赛沃药业有限公司 | 一种帕利哌酮植入剂及其制备方法 |
| SI3506921T1 (sl) * | 2016-08-31 | 2023-10-30 | Mapi Pharma Ltd. | Depojski sistemi, ki vsebujejo glatiramer acetat |
| JP7337080B2 (ja) * | 2017-10-27 | 2023-09-01 | 嘉奥制薬（石家庄）有限公司 | パリペリドンパルミチン酸エステル徐放性懸濁注射液の投薬レジメン |
| CN111989068A (zh) | 2018-05-24 | 2020-11-24 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| WO2019226516A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| JP2023552149A (ja) | 2020-11-30 | 2023-12-14 | ヤンセン ファーマシューティカ エヌ．ベー． | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
| US11439647B2 (en) | 2020-11-30 | 2022-09-13 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| FI4025188T3 (fi) | 2020-11-30 | 2024-02-21 | Janssen Pharmaceutica Nv | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2819769C (en) * | 2003-07-18 | 2016-06-28 | Oakwood Laboratories, L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| ATE401868T1 (de) | 2004-08-04 | 2008-08-15 | Alza Corp | ZUSAMMENSETZUNG MIT VERZÖGERTER ARZNEIMITTELFREISETZUNG MIT EINEM AUFSTEIGENDEN NULLORDNUNG-FREIGABE-MUSTER; VERFAHREN ZUR HERSTELLUNG EINER SOLCHEN ZUSAMMENSETZUNGß |
| US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US8314110B2 (en) | 2007-04-19 | 2012-11-20 | Youxin Li | Compounds for treating mental disorders, and preparation and uses thereof |
| CA2687979C (en) * | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of risperidone compounds |
| US20090036470A1 (en) | 2007-07-27 | 2009-02-05 | Jiri Bartl | Paliperidone derivatives |
| ES2868353T3 (es) | 2007-12-19 | 2021-10-21 | Janssen Pharmaceutica Nv | Régimen de dosificación asociado a ésteres de paliperidona inyectables de larga acción |
| WO2011042453A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| LT2394663T (lt) * | 2010-05-31 | 2022-02-10 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams |
| SI2529756T1 (sl) * | 2011-05-31 | 2021-09-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija vsadka z risperidonom in/ali paliperidonom |
| ES2456917T3 (es) * | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
-
2012
- 2012-05-31 ES ES12170366.4T patent/ES2456917T3/es active Active
- 2012-05-31 SI SI201230022T patent/SI2529757T1/sl unknown
- 2012-05-31 EP EP12170366.4A patent/EP2529757B1/en active Active
- 2012-05-31 PT PT121703664T patent/PT2529757E/pt unknown
- 2012-05-31 DK DK12170366.4T patent/DK2529757T3/en active
- 2012-05-31 PL PL12170366T patent/PL2529757T3/pl unknown
-
2013
- 2013-05-31 BR BR112014029208A patent/BR112014029208B1/pt active IP Right Grant
- 2013-05-31 EA EA201401348A patent/EA029921B1/ru unknown
- 2013-05-31 CN CN201910004281.0A patent/CN109966239A/zh active Pending
- 2013-05-31 MX MX2014014484A patent/MX365097B/es active IP Right Grant
- 2013-05-31 KR KR1020147036778A patent/KR101892496B1/ko active IP Right Grant
- 2013-05-31 IN IN10673DEN2014 patent/IN2014DN10673A/en unknown
- 2013-05-31 NZ NZ703319A patent/NZ703319A/en unknown
- 2013-05-31 UA UAA201414185A patent/UA115987C2/uk unknown
- 2013-05-31 MY MYPI2014703550A patent/MY181549A/en unknown
- 2013-05-31 WO PCT/EP2013/061319 patent/WO2013178811A1/en active Application Filing
- 2013-05-31 AU AU2013269546A patent/AU2013269546B2/en active Active
- 2013-05-31 JP JP2015514532A patent/JP6430933B2/ja active Active
- 2013-05-31 CA CA2874702A patent/CA2874702C/en active Active
- 2013-05-31 SG SG11201407971QA patent/SG11201407971QA/en unknown
- 2013-05-31 CN CN201380028041.5A patent/CN104349792A/zh active Pending
-
2014
- 2014-02-19 HR HRP20140158AT patent/HRP20140158T1/hr unknown
- 2014-02-26 CY CY20141100156T patent/CY1114975T1/el unknown
- 2014-04-03 SM SM201400044T patent/SMT201400044B/xx unknown
- 2014-11-23 IL IL235850A patent/IL235850A0/en active IP Right Grant
- 2014-11-26 CL CL2014003215A patent/CL2014003215A1/es unknown
- 2014-11-28 PH PH12014502668A patent/PH12014502668A1/en unknown
- 2014-12-16 MA MA37661A patent/MA37661B1/fr unknown
- 2014-12-17 ZA ZA2014/09297A patent/ZA201409297B/en unknown
- 2014-12-30 CO CO14285846A patent/CO7160109A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502668B1 (en) | Paliperidone implant formulation | |
| PH12014502667B1 (en) | Risperidone or paliperidone implant formulation | |
| RS53205B (en) | IMPLANTABLE PALIPERIDON FORMULATION | |
| UA108885C2 (uk) | Композиція рисперидону для ін'єкційної депо-форми | |
| MX2018002462A (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos. | |
| WO2011112996A3 (en) | Injectable drug delivery system | |
| MX2018001499A (es) | Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos. | |
| SA517381298B1 (ar) | تركيبة صيدلية بثبات محسن | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| MY195509A (en) | Pharmaceutical Formulations for Sustained Release of Sebacoyl Dinalbuphine Ester | |
| WO2014100735A3 (en) | Diazole amides | |
| WO2014119985A3 (es) | Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral | |
| IN2012CH05549A (es) | ||
| WO2015161841A3 (de) | Injizierbare und implantierbare trägersysteme auf basis von modifizierten poly(dikarbonsäure-polyol estern) zur kontrollierten wirkstofffreisetzung | |
| TR201005911A2 (tr) | Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu. | |
| TH127479B (th) | องค์ประกอบออกฤทธิ์ประวิงชนิดฉีดที่รักษาโรคจิต |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |